LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

Home・Список акций・Twist Bioscience Corp

Twist Bioscience Corp

Открыт

СекторЗдравоохранение

54.71 -2.7

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

52.75

Макс.

55.98

Ключевые показатели
By Trading Economics
Доход	-14M -44M
Продажи	7M 111M
Прибыль на акцию	-0.597
Рентабельность продаж	-39.761
Сотрудники	979
EBITDA	-16M -40M

Рекомендации
By TipRanks
Рекомендации	Активная покупка
Прогноз на 12 месяцев	+12.84% upside

Дивиденды
By Dow Jones
Следующий отчет о доходах	3 авг. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	843M 3.4B
Предыдущая цена открытия	57.41
Предыдущая цена закрытия	54.71

Новостные настроения

By Acuity

50%

150 / 346 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Very Strong Bearish Evidence

31.56 / 38.6884 Поддержка и Сопротивление

Twist Bioscience Corp График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

12 мая 2026 г., 22:50 UTC

Отчет

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

12 мая 2026 г., 22:49 UTC

Отчет

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

12 мая 2026 г., 22:32 UTC

Отчет

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

12 мая 2026 г., 23:48 UTC

Обсуждения рынка

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

12 мая 2026 г., 22:57 UTC

Обсуждения рынка

Отчет

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

12 мая 2026 г., 22:26 UTC

Отчет

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

12 мая 2026 г., 22:25 UTC

Отчет

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

12 мая 2026 г., 22:25 UTC

Отчет

Aristocrat Leisure Interim Dividend A$0.50/Security

12 мая 2026 г., 22:24 UTC

Отчет

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

12 мая 2026 г., 22:23 UTC

Отчет

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

12 мая 2026 г., 22:23 UTC

Отчет

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

12 мая 2026 г., 22:19 UTC

Отчет

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

12 мая 2026 г., 22:14 UTC

Отчет

CBA: Business Lending Continued to Grow Above System>CBA.AU

12 мая 2026 г., 22:14 UTC

Отчет

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

12 мая 2026 г., 22:13 UTC

Отчет

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

12 мая 2026 г., 22:12 UTC

Отчет

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

12 мая 2026 г., 22:12 UTC

Отчет

CBA 3Q New Home Loan Funding A$45B>CBA.AU

12 мая 2026 г., 22:11 UTC

Отчет

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

12 мая 2026 г., 22:11 UTC

Отчет

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

12 мая 2026 г., 22:10 UTC

Отчет

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

12 мая 2026 г., 22:09 UTC

Отчет

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

12 мая 2026 г., 22:09 UTC

Отчет

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

12 мая 2026 г., 22:08 UTC

Отчет

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

12 мая 2026 г., 22:07 UTC

Отчет

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

12 мая 2026 г., 22:06 UTC

Отчет

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

12 мая 2026 г., 22:06 UTC

Отчет

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

12 мая 2026 г., 22:05 UTC

Отчет

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

12 мая 2026 г., 22:04 UTC

Отчет

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

12 мая 2026 г., 22:04 UTC

Отчет

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

12 мая 2026 г., 22:04 UTC

Отчет

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Сравнение c конкурентами

Изменение цены

Twist Bioscience Corp Прогноз

Целевая цена

By TipRanks

12.84% рост

Прогноз на 12 месяцев

Средняя 63.43 USD 12.84%

Максимум 70 USD

Минимум 56 USD

Основано на мнении 7 аналитиков Wall Street, спрогнозировавших целевые цены для Twist Bioscience Corp на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

7 ratings

Покупка

Удержание

Продажа

Основано на мнении 7 аналитиков, присваивавших рейтинги акциям Twist Bioscience Corp – Данные за последние 3 месяца.

Техническая оценка

By Trading Central

31.56 / 38.6884Поддержка и Сопротивление

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

Настроения

By Acuity

150 / 346Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.